Publications
Page 8 of 9
November 24, 2015
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition
Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA…
Journal: Journal of Neuroimmunology
November 6, 2015
Accelerating pancreatic cancer drug screening by leveraging genomics to select better in vitro models.
Cell lines used for pre-clinical testing of oncology compounds are not always chosen based on how well they models patient tumors. Instead they are often chosen based on availability and…
September 23, 2015
Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
To generate new insights into the biology of Alzheimer’s Disease (AD), we developed methods to combine and reuse a wide variety of existing data sets in new ways. We first…
Journal: Scientific Reports
August 1, 2015
Improving pancreatic cancer drug discovery by leveraging genomics to select better in vitro models
Currently, pancreatic cancer has an estimated 5-year survival rate of only 5-6%. The projection that pancreatic cancer will be the second leading cause of cancer related death by 2020 compounded…
June 25, 2015
Glatiramoids
Glatiramoids are non-biologic complex drugs (NBCDs) comprising four naturally occurring amino acids in a complex copolymeric mixture. The first and most thoroughly studied glatiramoid, glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries,…
May 22, 2015
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids
Sub Title Goes Here
Journal: Scientific Reports
September 8, 2014
Use of genetic technologies to compare medicines
In order to ensure that patients receive the safest and most effective medicines possible, it is often necessary to compare medicines and assess the extent to which they are similar…
Journal: Clinical Genetics
May 22, 2014
BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT
Provided herein are prognostic and diagnostic methods for predicting likelihood of clinical response of a subject having cancer to treatment with an immunotherapeutic agent. Also provided herein are methods for…
January 8, 2014
Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming…
Journal: PLoS One
March 26, 2013
Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune disease, this is particularly challenging because progression of disease is lengthy and…
Page 8 of 9
